<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709134</url>
  </required_header>
  <id_info>
    <org_study_id>178-2018</org_study_id>
    <nct_id>NCT03709134</nct_id>
  </id_info>
  <brief_title>Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy</brief_title>
  <official_title>Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is to identify genomic markers (circulating tumor cells (CTCs),
      circulating tumor DNA (ctDNA), transcriptomic markers) as biomarkers of response to
      neoadjuvant chemotherapy (NAC) among patients with invasive breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to evaluate genetic markers (i.e. CTCs and ctDNA) in breast tumors to predict
      therapy response and metastatic risk. We aim to investigate genomic markers of treatment
      response and outcomes in breast cancer patients treated with neoadjuvant chemotherapy. The
      role of CTCs and ctDNA in predicting response to NAC will also be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Pathologic complete response (pCR)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Evaluating the degree of absence of residual cancer cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to distant breast cancer recurrence (months)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Evaluating the time until a recurrence event has occurred in the breast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to any recurrence (months)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Evaluating the time until a local, regional, or distant recurrence event has occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Evaluating time to cancer-related death</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Cancer, Breast</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Genomic Markers (CTC/ctDNA)</intervention_name>
    <description>This is a non-interventional study.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll women and men with a pathologically-confirmed diagnosis of invasive
        breast cancer that is stage I-III according to the AJCC v7 criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must give appropriate written informed consent prior to participation in the
             study.

          2. Subjects must be women or men age 18+.

          3. Subjects must be receiving neoadjuvant chemotherapy for breast cancer. All
             chemotherapy types and regimens are acceptable (systemic therapy will determined by
             the overseeing medical oncologist).

          4. Biopsy-confirmed diagnosis of invasive breast cancer (i.e. ER+/-, PR+/-, HER2+/-).

          5. Stage I-III disease according to the AJCC v7 criteria.

        Exclusion Criteria:

          1. Subjects with a past medical history of abnormalities, significant injury, or medical
             or surgical procedures (e.g. silicone/saline implants) involving either breast,
             exclusive of the lesion at issue.

          2. Subjects, who, in the opinion of the investigator or clinical research coordinator,
             may not otherwise be appropriate for inclusion into the study, such as significant
             anxiety.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katarzyna J Jerzak, MD, MSc, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarzyna J Jerzak, MD, MSc, FRCPC</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>5248</phone_ext>
    <email>katarzyna.jerzak@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>William T Tran, MSc, PhD, MRT(T)</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>3746</phone_ext>
    <email>william.tran@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna J Jerzak, MD, MSc, FRCPC</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>5248</phone_ext>
      <email>katarzyna.jerzak@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>William T Tran, MSc, PhD, MRT(T)</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>3746</phone_ext>
      <email>william.tran@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Kasia J Jerzak, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 12, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. Katarzyna Jerzak</investigator_full_name>
    <investigator_title>Medical Oncologist &amp; Associate Scientist</investigator_title>
  </responsible_party>
  <keyword>Circulating tumor cells</keyword>
  <keyword>CTC</keyword>
  <keyword>Circulating tumor DNA</keyword>
  <keyword>ctDNA</keyword>
  <keyword>Genomics</keyword>
  <keyword>Transcriptomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

